Shamburg News · 8-K filed Nov 13, 2026, 6:02 AM EST

Nektar Therapeutics Reports $952.9 Million Cash and Investments as of September 30, 2026

NKTR · NEKTAR THERAPEUTICS

  • Reg FD disclosure
  • Financial statements
  • Materiality: medium

Nektar Therapeutics furnished under Regulation FD that it reported $952.9 million in cash and investments in marketable securities as of September 30, 2026, in conjunction with its third quarter financial results announced November 12, 2026. The company stated that this balance is expected to extend its cash runway into the third quarter of 2028, past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis expected in the summer of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 7.01, accession 0001213900-26-119146.

Written from the filing by Shamburg Markets. Figures are as reported by the company.